Kansas has filed a third lawsuit stemming from its ongoing antitrust investigation into a widespread conspiracy by generic drug manufacturers to artificially inflate and manipulate prices, reduce competition and unreasonably restrain trade for generic drugs sold across the United States. Attorney General Derek Schmidt announced on Wednesday, that the lawsuit focuses on 83 topical generic drugs that account for billions of dollars of sales in the United States. The complaint names 26 corporate defendants and 10 individual defendants. It seeks damages, civil penalties and actions by the court to restore competition to the generic drug market. The topical drugs at the center of the complaint include creams, gels, lotions, ointments, shampoos, and solutions used to treat a variety of skin conditions, pain, and allergies. The complaint alleges longstanding agreements among manufacturers to ensure a “fair share” of the market for each competitor, and to prevent “price erosion” due to competition. The new complaint, brought by a coalition of 51 states and territories including Kansas, is the third to be filed in an ongoing, expanding investigation into generic drug price fixing.